Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Harvard Business School
Dow
Johnson and Johnson
Boehringer Ingelheim

Last Updated: June 27, 2022

CLINICAL TRIALS PROFILE FOR OPICAPONE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Opicapone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01227655 ↗ Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. Completed Bial - Portela C S.A. Phase 3 2011-03-01 Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year. BIA 9-1067 is currently being developed by BIAL (Portela & CÂȘ,S.A.) to be used in addition to L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients. Promising results have been obtained for BIA 9-1067 in previous studies.
NCT01515891 ↗ Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Completed Bial - Portela C S.A. Phase 1 2009-05-01 To determine the absorption, metabolism and excretion of BIA 9-1067.
NCT01851850 ↗ Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial Completed Rabin Medical Center Phase 3 2013-05-01 The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.
NCT02101190 ↗ Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment Completed Bial - Portela C S.A. Phase 1 2010-03-01 The purpose of this study is to assess the pharmacokinetics (PK) of BIA 9-1067 in patients with moderate chronic hepatic impairment and in matched healthy subjects.
NCT02170376 ↗ The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics Completed Bial - Portela C S.A. Phase 1 2011-09-01 The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg entacapone (ENT).
NCT02305017 ↗ Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers Completed Bial - Portela C S.A. Phase 1 2014-03-01 Single-centre, open-label, randomised, two-way cross-over study consisting of 2 periods separated by a washout period of 14 days or more.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Opicapone

Condition Name

Condition Name for Opicapone
Intervention Trials
Parkinson Disease 11
Parkinson's Disease 4
Parkinson 2
Parkinson's Disease (PD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Opicapone
Intervention Trials
Parkinson Disease 18
Epilepsy 1
Sleep Wake Disorders 1
Parasomnias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Opicapone

Trials by Country

Trials by Country for Opicapone
Location Trials
United Kingdom 3
Portugal 2
France 2
United States 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Opicapone
Location Trials
Michigan 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Opicapone

Clinical Trial Phase

Clinical Trial Phase for Opicapone
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 1 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Opicapone
Clinical Trial Phase Trials
Completed 15
Recruiting 4
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Opicapone

Sponsor Name

Sponsor Name for Opicapone
Sponsor Trials
Bial - Portela C S.A. 17
Rabin Medical Center 1
Neurocrine Biosciences 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Opicapone
Sponsor Trials
Industry 19
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Express Scripts
AstraZeneca
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.